Advanced ovarian clear cell carcinoma (OCCC) carries a very poor prognosis in large part secondary to the extremely high rate of resistance to standard platinum and taxane chemotherapy. Signal transducer and activator of transcription 3(STAT3) expression and activation has been shown to regulate tumor progression in various human cancers, though has not been well studied in OCCC. Preliminary work in our lab has demonstrated constitutive activation of STAT3 (pSTAT3Tyr705 or pSTAT3727) in OCCC cell lines as well as human OCCC tumor tissue samples. Significantly, pSTAT3 is expressed in the absence of other forms of activated STAT (pSTAT1, 2, 6). Therefore, this work was planned to investigate the role of STAT3 and examine the efficacy of a novel anti-cancer compound -HO-3867, which is an inhibitor of STAT3, using known OCCC cell lines. Results demonstrate that treatment with HO-3867 decreased expression of pSTAT3 Tyr705 as well pSTAT3 Ser727, while total STAT3 remained constant. STAT3 overexpression increased the migration capability in OVTOKO cells in vitro and led to an increased tumor size when injected in vivo. The inhibitory effect of HO-3867 on cell proliferation and cell survival was accompanied by increased apoptosis, within 24 h post treatment. Treatment with HO-3867 resulted in a decrease in Bcl-2 and increase of cleavage of caspase 3, caspase 7, and PARP, confirming induction of apoptosis after treatment with HO-3867. In addition, HO-3867 significantly inhibited formation of human umbilical vein endothelial cells capillary-like structures and invasion at both 5 and 10 mM concentrations. STAT3 expression plays an important role in the spread of OCCC in vitro as well as in vivo. Thus, we can exploit the STAT3 pathway for targeted drug therapy. Inhibition of pSTAT3 using HO-3867in OCCC cell lines appears to be a promising therapy. This is of utmost importance given the poor response of OCCC to standard chemotherapy regimens.
Introduction
Ovarian clear cell carcinoma (OCCC) accounts for approximately 5-25% of epithelial ovarian cancers (EOCs) with varying incidence by population. [1] [2] [3] Though rare, it presents a unique treatment challenge. Although OCCC tends to present at earlier stages, women with advanced disease have a poor prognosis compared with other EOC subtypes. [3] [4] [5] This is illustrated by a meta-analysis of multiple clinical trials of advanced-stage EOC that noted a median overall survival of 21.3 months for women with OCCC, compared with 40.8 months for those with high grade serous ovarian cancer (HGSOC). 5 It has been hypothesized that the discrepancy in outcomes may be at least in part secondary to tumor resistance to chemotherapy. Although platinum-based chemotherapy is standard first-line treatment for EOC, OCCC does not respond well to the regimen. In a multi-center retrospective study of patients with stage III/IV OCCC with measurable disease after surgery, response to platinum-based chemotherapy was 11.1%, as compared with 72.5% in patients with HGSOC. 4 Another analysis of data from multiple clinical trials for advanced ovarian cancer found that overall response rates were 45% for OCCC versus 81% for HGSOC. 6, 7 Although the relative chemoresistance of OCCC is felt to portend a worse prognosis, the precise mechanism of resistance remains unclear. Thus, to improve outcomes for patients diagnosed with OCCC, it is critical to find ways to overcome chemoresistance or identify new targets for therapy. Signal transducer and activator of transcription 3 (STAT3) is a transcription factor that mediates cytokine and growth factor signaling. STAT3 activation contributes to tumorigenesis by promoting cell proliferation, survival, angiogenesis, metastasis, inflammation, and immune evasion. tumor progression in various human cancers including HGSOC, though has not been well studied in OCCC. OCCC is characterized by a high rate of ARID1A and PI3K mutations which have been shown to cooperate in animal models to promote OCCC tumor growth through sustained IL-6 overproduction leading to increased activation of STAT3. 12 Additionally, Anglesio et al. 13 demonstrated overexpression of IL6-STAT3-HIF pathway in OCCC. These findings support further investigation into STAT3 as a potential therapeutic target in OCCC.
We have previously shown that activation of STAT3 is necessary for HGSOC tumor progression/metastasis and targeting STAT3 with HO-3867 (a member of a novel class of anticancer drugs, diarylipenylpiperiden-4-ones (DAP's) significantly suppressed tumor growth and metastasis. 10, [14] [15] [16] Therefore, this study was designed (i) to investigate and establish the role of STAT3 in OCCC progression in OCCC cells and human OCCC patient tissue samples (ii) to examine the efficacy of our STAT3 inhibitor, HO-3867 in vitro and in vivo using the orthotopic tumor model.
Material and Methods

Culture of OCCC cells
The OCCC cell lines OVTOKO, JHOC, OVISE and ES2 were a kind gift from Ikuo Konishi, Kyoto Medical University, Japan. The cells were cultured in T75 flasks in RPMI medium supplemented with FBS (10%) and Penicillin/streptomycin (1%).
Immunocytochemistry
Cells in RPMI medium were seeded onto sterile glass coverslips in 6-well plates with an average population of 50,000 cells/well. After 24 hr of culture, the cells were washed, fixed, and incubated with primary antibody according to a previously described protocol.
STAT3 overexpression/knockdown experiments
For downregulation of STAT3 in OVTOKO cells, a lentiviral system with a set of different siRNA -short-interfering Lentiviral Particles, Santa Cruz Biotechnology, TX) using Dharmafect Transfection Reagent (GE, Lafayette, CO) in OVTOKO cells. For STAT3 overexpression (STAT3 OE), we used EF.STAT3C.UbC.GFP, which was a gift from Linzhao Cheng (Addgene plasmid no. 24983), transfected into OVTOKO cells using Dharmafect Transfection Reagent (GE, Lafayette, CO).
Immunoblot analysis
Cells were treated with HO-3867 (5 or 10 lM) for 24 hr. Following treatment, the cell lysates were prepared in nondenaturing lysis buffer as previously described. 17 
Cell migration assay
Cell migration assays were performed on both treated and nontreated cells using a wound-healing method. 18 RNA isolation and reverse transcription PCR OVTOKO cells were counted and plated in equal numbers in petridishes. The petridishes were treated with HO-3867 at 5 and 10 mM concentrations, with at least three plates per treatment. At 24 hr posttreatment, the cells were collected and stored in the 2808C until further use. Total RNA was isolated using the RNeasy Mini Kit (Qiagen, Valencia, CA). RNA samples with an optical density A260/A280 ratio between 1.8 and 2.1 were used. Reverse transcription PCR (RT-PCR) was then performed using the Transcriptor First Strand Complementary DNA (cDNA) Synthesis Kit (Roche Applied Science) to synthesis cDNA. RT-PCR was performed with 1 mg of RNA template. The reaction was carried out using the Veriti Thermal Cycler (Applied Biosystems, Carlsbad, CA) and random hexamer primers.
Quantitative real time PCR
The genes studied for their relative genetic expression patterns are provided in Supplementary Table 1 Table 1 ). qRT-PCR was performed using the Light Cycler 480 System (Roche Applied Science). Each sample was normalized to the control gene glyceraldehyde 3-phosphate dehydrogenase (GAPDH).
STAT3 DNA-binding assays
After treatment with HO-3867 for 24 hr, a nuclear extract kit (Clontech Inc., Mountain View, CA) was used to prepare cell nuclear extracts following the manufacturer's protocol. Nuclear extracts were analyzed for STAT3 DNA binding activity using the TransFactor Universal STAT3-specific kits (Clontech Inc., Mountain View, CA) with an ELISA-based method.
Ubiquitin assay
To trace the ubiquitinated proteins in the cell lysates, agarose beads coated with domains having affinity to ubiquitin were incubated in the lysates at 48C for 2 hr. After washing the beads, the ubiquitinated proteins were subjected to immunoblot for pSTAT3 and blotted by the ubiquitin antibody. 19 
What's new?
The overall clinical response in chemotherapy-treated patients with recurrent ovarian clear cell carcinoma (OCCC) is only 25-40%. Development of new treatment approaches is urgently needed to improve the survival of patients afflicted with the disease. Here, the authors find high levels of expression of phosphorylated STAT3 (pTyr705 and pSer727) in OCCC and propose that this may represent a new chemoresistant pathway in these cancers.
Evaluation of the bioabsorption of DAPs in ovarian cancer cells using electron paramagnetic resonance Our previous study showed that cellular uptake of HO-3867 was significantly greater than curcumin. 20 We evaluated the bio absorption of HO-3867 compounds in ES2 and OVTOKO cells after 1, 3, and 6 hr posttreatment, using electron paramagnetic resonance (EPR), as previously described. 21 Development of orthotopic tumor model STAT3 OE OCC cells (3 3 10* 6 cells in 100 lL of PBS) were injected into the ovarian bursa of 6-week-old BALB/c nude mice from the OSU Transgenic mice core lab. In vivo MRI imaging was done periodically to check upon the tumor growth. After sacrifice, the tumor weight and volume was measured.
Statistical analysis
Data are presented as mean 6 1 SD
Results
Validate the expression of STAT3 in OCCC cell lines and human patient tissue samples
We received 7 OCCC tissue samples from consented patients with OCCC at our institution and analyzed the expression of pSTAT3 Tyr705, pSTAT3 Ser727 and total STAT3. Five out of seven samples showed moderate to high expression of pSTAT3Tyr705 on Western Blot (Fig. 1a) . Expression was tested in OCCC cell lines (JHOC and OVTOKO). The studied cell lines showed moderate to high expression of pSTAT3 Tyr705, Ser727 and total STAT3, when analyzed by western blot (Fig. 1b) . pSTAT3 Tyr705 showed high expressions in both tested cell lines (Fig. 1b) . OVTOKO cells (90-95%) showed pSTAT3 Tyr705 localized in the nucleus as well as the cytoplasm while pSTAT3 Ser727 was mostly found in the cytoplasm of OVTOKO cells (Fig. 1c) .
Effect of STAT3 OE or knockdown in OCCC cells in vitro as well as in vivo
In our previous studies with HGSOC, we found that the knockdown of STAT3 causes reduction in tumor growth and metastases in vivo. 10 Based on this finding, we considered it imperative to determine if STAT3 plays a role in cell proliferation, migration, and survival of OCCC cell lines as well. Therefore, we developed OVTOKO STAT3 OE cells by transfecting OVTOKO cells with a plasmid construct constitutively expressing pSTAT3 Tyr705. Figure 2a shows the western blot expression of pSTAT3 Tyr705 in 4 of the tested OE clones. We found that clone O6 showed the highest expression of pSTAT3 Tyr705 so we moved forward with this clone for our future studies. This was further confirmed at the mRNA level using real time quantitative PCR to check the relative expression of genes related to angiogenesis, cell survival and cell proliferation. The relative mRNA expression of STAT3 was highest in OVTOKO STAT3 OE cells followed by the control OVTOKO cells and OVTOKO STAT3 KO cells (Fig. 1f) . The STAT3 target genes like Survivin, VEGF, c-myc and BCl2 were highest in the OVTOKO STAT3 OE cells and least in the OVTOKO STAT3 KO cells (Fig. 1f) . Taken together, these results suggest that deleting STAT3 inhibits the expression of a number of genes responsible for cell survival, proliferation and angiogenesis. These findings were further evaluated in vivo. The OVTOKO control and OVTOKO STAT3 OE cells were injected into the right ovarian bursal cavity of nude mice (Fig. 2g) . It is noteworthy that the mice injected with control OVTOKO cells failed to develop any primary tumor in the first 5 weeks postinoculation. However, the mice injected with OVTOKO STAT3 OE cells developed significantly large tumors as demonstrated in Figure 2h . No metastases were observed in any of the cases. These results add support to the role of STAT3 in OCCC tumor development and growth, and its ability to regulate the expression of different genes involved in survival and proliferation.
HO-3867 targets STAT3 and its associated genes in OCCC cells
We used OVTOKO and JHOC cell lines to test the therapeutic efficacy of our previously developed novel DAP compound on OCCC cell lines. We treated OVTOKO and JHOC cells with two different concentrations (5 and 10 mM) of HO-3867. Western blot expression in Figure 3a clearly shows that the expression levels of both pSTAT Tyr705 and pSTAT Ser727 drastically decreases even in the lowest dose of 5 mM and is almost non-existent in the higher dose of 10 mM for both the tested OCCC cell lines (Fig. 3b) . To determine whether HO-3867 inhibited pSTAT3 DNA-binding activity, OVTOKO and JHOC cells were treated with 10 mM of HO- 3867, and samples were subjected to ELISA assay. HO-3867 compound inhibited STAT3 DNA binding activity in both cells when compared with control (Fig. 3c) . Further, the STAT3 regulated genes like JAK1, Tyk2, and CDK5 also showed a diminished expression post treatment with HO-3867 for both the tested OCCC cell lines. MCL1, BCl2, Cyclin D2, and c-myc were also decreased post HO-3867 treatment for both JHOC and OVTOKO cells (Figs. 3d and 3e) . This demonstrates that HO-3867 effectively targets STAT3 and its associated genes in OCCC cells. We sought to confirm these findings at the level of relative mRNA expression using qRT-PCR. The RNA obtained from the treated OVTOKO cells was converted to cDNA and subjected to real time PCR using the gene specific primers for STAT3, JAK1, BCl2, c-myc and cyclin D1. We found that mRNA expression for STAT3 and JAK1 was decreased post treatment with HO-3867 at both the doses of 5 and 10 mM. However, the expression levels of BCl2, c-myc and cyclin D1 were not significantly decreased after treatment with HO-3867 (Fig. 3f) .
Ubiquitination is the first step of the ubiquitinproteasome pathway that regulates cells for their homeostatic functions and is an enzymatic, protein posttranslational modification process in which ubiquitin is transferred to a target protein substrate by a set of three ubiquitin enzymes. [23] [24] [25] Given the importance of this process, it is plausible that HO-3867 has a function to regulate the ubiquitination. Therefore, we examined the ubiquitination status of the OVTOKO cells post treatment with HO-3867 and observed an enhanced degradation in both OVTOKO and JHOC cells post treatment for both the concentrations. Further, the degradation was concentration specific and increased with the increasing dosage of HO-3867 (Fig. 3g) .
HO-3867 inhibits cell survival and increases the caspase cascade pathway
To evaluate the effect of HO-3867 on OCCC survival, we treated cells with different concentrations (1, 2.5, 5, 10, and 20 mM) of HO-3867 at time points (24 and 48 hr). Cell viability was measured by MTT assay and cell count. The proliferation and survival of OCCC cells were inhibited by HO-3867 in a dose-dependent manner (Fig. 4a) . Caspases are aspartic acid-specific proteases and are the major effectors of apoptosis. Therefore, in order to confirm if the activity of HO-3867 also activates the caspase cascade, we performed western blot on OVTOKO, ES-2, OVISE, and JHOC cells and found that PARP, cleaved caspase 3 and cleaved caspase 9 were all upregulated post treatment with HO-3867 (Fig.  4b) . As an additional proof of concept experiment, we further studied the caspases in ES2 and OVISE cells and found that the higher dose of 20 mM was able to activate cleaved caspase 3 and cleaved caspase 7 and poly(ADP-ribosyl)-transferase (PARP) was activated even by the lower dose of 10 mM (Fig. 4b) . This was further confirmed by Annexin V staining assays using a flow cytometer. It is known that in early stages of apoptosis, the plasma membrane excludes viability dyes such as propidium iodide (PI) and display only Annexin V staining. We observed an increase in the percent of Annexin V positive cells with 30-51% of apoptotic cells post treatment as compared with 5-10% cells undergoing apoptosis in the untreated cells (Figs. 4c and  4d) . The HO-3867-treated STAT3-overexpressing cells showed increased cell proliferation and decreased apoptotic proteins, in comparison with HO-3867 alone treated cells (Figs. 4e and 4f) , suggesting that HO-3867 might target, at least in part, STAT3 in OCCC. EPR spectrum obtained from ovarian clear cell carcinoma showing the presence on HO-3867 in the oxidized (nitroxide) form. HO-3867 levels in the cell samples were determined using EPR, clear, triplet signals indicating the presence of the -NO_ radical (nitroxide) form of HO-3867 were obtained from both cell lines and quantified (Figs. 4g and 4h) .
Effect of HO-3867 on human umbilical vein endothelial cells
In the ovarian clear cell tumor microenvironment, tumor cells secrete vascular endothelial growth factor (VEGF) and other angiogenic factors that promote the growth and assembly of neighboring endothelial cells. Since HO-3867 can block secretion of important angiogenic proteins, we next examined if HO3867 treatment suppresses the growth and differentiation of human umbilical vein endothelial cells (HUVEC) in response to treatment with VEGF. HO-3867 significantly inhibited formation of capillary-like structures at both 5 and 10 mM concentrations (Fig. 5a ), indicating that signaling through STAT3 is necessary for VEGF-stimulated proliferation and tube formation of these endothelial cells. A 3D angiogenesis model utilizing VEGF stimulated HUVEC spheroids embedded in a collagen matrix recapitulates the inhibition of tube-like formation by HO3867 seen in the 2D model. After successful stimulation, new blood vessels sprouted into the collagen matrix within 2-3 days and were quantified in the presence and absence of HO-3867. Fewer number and shorter length of the sprouts demonstrates the anti-angiogenic activity of HO-3867 in comparison to the control group (Fig. 5b) . HO-3867 treatment also significantly blocked the invasion of VEGF-stimulated HUVECs through a Boyden chamber (Fig. 5c) .
Cytosolic STAT3 is known to be a co-regulator of Factin fiber 26 and microtubule 27 formation. The disruption of lamellipodia formation and microtubule breakdown at the trailing edge may explain the drastically reduced invasion of HUVEC cells. In order to confirm this, HUVEC cultures were treated with VEGF alone, VEGF plus DMSO (drug vehicle) or VEGF with HO-3867 for 18 hr followed by staining for F-actin and b-tubulin (Fig. 5d) . Thin, uniform fibers spanning the length of the cells were characteristic of the F-actin in the control and VEGF-treated cultures, with greater localization at the peripheral lamellipodia and intercellular junctions. The microtubules extended to the periphery of the cells forming a dense lattice that emanated from the center of the cells. However, in STAT3 inhibited cultures, the cells displayed a condensed and rounded morphology. The actin had condensed into fewer fibers, and most strikingly, was completely absent from the leading edges of the cells (white arrows, Fig. 5d ). The microtubule structures were additionally affected by the HO-3867 treatment. As highlighted by the arrowheads in Figure 5d , tubulin staining still showed that the microtubules emanated from the nuclear region of the HUVEC cells, but at the periphery, they curled over.
Discussion
Our results indicate high levels of expression of phosphorylated STAT3 (pSTAT3Tyr705 and Ser727) in OCCC which may prove to be an important pathway for OCCC cell survival, proliferation, and angiogenesis. Further, this is the first report demonstrating efficacy of HO-3867, a curcumin analog, in OCCC. Here we show that treatment with HO-3867 results in inhibition of OCCC cell survical and proliferation, induces apoptosis, and inhibits angiogenesis.
Recent studies have identified potential driver genes and aberrant signaling pathways involved in development of OCCC. 7, 28, 29 As described earlier, ARID1A and PI3K mutations are detected in >55 and 30% of OCCC cases, respectively. 2, 12 Co-existent ARID1A and PI3K mutations have been shown to promote OCCC tumor growth through overproduction of IL-6 and activation of STAT3 lending STAT3 an attractive target for therapy. 12, 13 Although, the expression of STAT3 oncogene is well known in HGSOC, 9, 10, 30, 31 moderately little is known about the STAT3 signaling pathways in OCCC; its involvement in chemo-resistance and poor survival or its potential as a therapeutic target. This study identified (i) the expression of STAT3 in OCCC patient tissues and cell lines and (ii) STAT3 expression can up-regulate its target genes such as c MYC (proliferation), and Bcl-2 (cell survival and anti-apoptotic) thus playing a key role in proliferation and tumor progression of OCCC. Recent studies in renal clear cell carcinoma have associated higher expression of pSTAT3 with the tumor grade and poor patient survival. 32, 33 It is clearly evident from our study that the expression of STAT3 might affect patient survival in OCCC, and targeting STAT3 using small molecule inhibitors could possibly inhibit OCCC tumor growth and help overcome the chemotherapeutic resistance in OCCC tumors.
We have recently reported four promising DAP compounds which are STAT3 inhibitors-H-4073, HO-3867, H-4318, and HO-4200. 15, 16, 34 HO-3867 demonstrating high cytotoxicity towards human ovarian cancer cells, including those known to be chemo-resistant, under both in vitro and in vivo conditions. 14 We have selected one of our best DAP compound STAT3 inhibitor-HO-3867, based on the STAT3 DNA-binding activity and selective cytotoxicity in cancer cells rather than normal epithelial cells, for the current study. HO-3867 significantly inhibits pSTAT3 in OCCC cells, through the upstream pathways of STAT3 such as JAK and TYK2. In addition, the current study showed an enhanced poly-ubiquitination of pSTAT3 by HO-3867 treatment in OCCC. These results suggest that in OCCC, HO-3867 targets STAT3 through dual pathways-the ubiquitin-dependent degradation of pSTAT3 and the inhibition of upstream regulators of pSTAT3, such as JAK1 and TYK2, eventually inhibiting cell proliferation and inducing apoptosis via modulating its target genes (Cyclin D1 and Bcl-2).
Targeting angiogenesis and VEGF is another therapeutic approach used in treatment of several solid tumors, OCCC included. 13, 35 VEGF was reported to be strongly expressed in OCCC cells and patient samples, both in early-and advanced-stage disease. High levels of VEGF expression are additionally associated with shorter survival than those with lower levels of VEGF expression in OCCC. 6, 35 In this study we document the direct effects of HO-3867, which include: suppression of HUVEC cell migration and invasion, tube formation of endothelial cells, and inhibition of microtubule assembly. This proves that STAT3 signaling closely governs these processes and affect STAT3 downregulated protein-VEGF in OCCC. Further, clinical evidence showed that sunitinib, a potent VEGF inhibitor, is more responsive in the treatment of clear cell carcinoma patients than serous tumors. 6, 36, 37 In conclusion, we demonstrate that pSTAT3 expression is highly elevated in OCCC tumors and is a potential therapeutic target for this disease. Our small molecule STAT3 inhibitor of HO-3867 efficiently inhibits pSTAT3 and its target proteins, thereby impeding cell proliferation, angiogenesis and cytotoxicity in OCCC and seems promising in the future treatment of OCCC.
